Navigation Links
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
Date:4/1/2009

SAN DIEGO, April 1 /PRNewswire/ -- Patients with schizoaffective disorder who received paliperidone extended release tablets (paliperidone ER) for six weeks showed significant improvement in a broad range of schizoaffective symptoms, according to a new study presented today at the 12th International Congress on Schizophrenia Research (ICOSR) in San Diego, Calif.(1) The findings of the study provide additional evidence for symptomatic improvement of schizoaffective disorder following therapy with paliperidone ER.(2)

"This well-designed and conducted study of paliperidone ER in patients with schizoaffective disorder found that this medication is both efficacious and well-tolerated," said Nina Schooler, Ph.D., SUNY Downstate Medical Center. "These new data support the potential use of paliperidone ER as an effective option for the treatment of this understudied group of patients."

Schizoaffective disorder is a condition, which encompasses the symptoms of both schizophrenia and a major mood disorder. Patients with schizoaffective disorder experience the psychosis characteristic of schizophrenia, such as hallucinations or delusions, as well as symptoms of mania and/or depression.(3) Schizoaffective disorder can be difficult to distinguish from schizophrenia or bipolar disorder because the symptoms are similar to both. The disorder is about one third as common as schizophrenia(4) but within those people that frequently use mental health services, schizophrenia and schizoaffective disorder may account for approximately 32% and 24% of cases respectively.(5)

In the six week, international, randomized, double-blind, placebo controlled study, 311 patients with an established diagnosis of schizoaffective disorder, who were experiencing acute symptoms, were randomized to receive either paliperidone ER or a placebo. The paliperidone ER dose was initiated at 6 mg/day and could be adjusted in range from 3mg/day
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Harvest Technologies Announces Interim Study Results From Critical Limb Ischemia Trial in Chennai India
2. Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
3. Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing
4. Joplin Citizens and Health Organizations Call on Missouri Gov. Nixon for Study, Action on High Incidence of Birth Defects and Chronic Diseases in Community
5. $5.5 million from Gates Foundation funds major study of childhood malnutrition
6. Study Casts Doubt on Influential Hospital Safety Survey
7. New Study Shows That Despite Recession, Consumer Hold-Outs Struggle To Have It All
8. Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
9. Study Links Pesticides to Birth Defects
10. Study Shows Patients & Nurses Benefit From Continuous Vigilance Monitoring
11. Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 (HealthDay News) -- The tragic death from "rat-bite fever" ... by the pet rodents, according to a report from the ... is a rare but potentially fatal illness that should be ... when a history of rodent exposure is reported," said a ... Intelligence Service. The case outlined in the report occurred ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
(Date:12/17/2014)... December 17, 2014 Unidesk Corporation ... Medicine (ACOM), which welcomed its inaugural class in ... (VDI) to seamlessly support bring your own device ... teaching – experience. The solution, comprised of ... Dell server and storage infrastructure and ...
(Date:12/17/2014)... In its comprehensive analysis of medical ... Claim Review division have recently identified out-of-network and medical ... savings are achieved on behalf of employer-clients. , ... in savings to Argus each year, with a total ... by Tom Doney, Cypress president and CEO, these in-depth ...
(Date:12/17/2014)... News) -- As gas prices rose in recent years, ... suggests. In times of gas increases, more people ... inexperienced, the researchers explained. They examined data gathered ... highest number of motorcycle registrations in the United States ... The analysis revealed a strong association between rising gas ...
Breaking Medicine News(10 mins):Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2
... ,It,s Totally Glam to Go for a Mammogram, and ... Men ,Don,t Wait to Check Your Prostate, DALLAS, ... across Texas are sending a different kind of love note to ... women can send an e-reminder to,schedule important cancer screenings that will ...
... ... ... it has begun shipping the new SILVER SEAL(TM) Washable, Antimicrobial,Keyboard. According ... keyboard to be fully submersible, dishwasher safe,and manufactured from SILVER SEAL(TM) ...
... ARLINGTON, Va., Feb. 12 As health care,continues ... election, The HealthCentral,Network, Inc.,s ( http://www.HealthCentral.com ) interactive ... credible tool for voters to determine,which candidate aligns ... Now, washingtonpost.com has chosen the tool for its ...
... 12 Thanks to the collective spirit,of three ... new event has been added to the 2008 ... Triathlon, and registration,is now open., The Ramblin, ... empowerment of women, bring together women of all ...
... a,leading provider of evidence-based nutraceuticals for eye health, today,announced ... its Scientific,Advisory Board., Dr. Coleman is a Professor ... David Geffen School of Medicine at UCLA as well ... Health. She holds,the Frances and Ray Stark Endowed Chair ...
... Transitions, ... Feb. 12 In an effort to heighten,consumer awareness ... debuting a new print, broadcast and digital integrated advertising,campaign ... TV and in print,and will be supported by the ...
Cached Medicine News:Health News:'His and Hers' Screening Campaign Offers Unique Valentine's Day Message to Increase Cancer Screenings and Promote Health 2Health News:'His and Hers' Screening Campaign Offers Unique Valentine's Day Message to Increase Cancer Screenings and Promote Health 3Health News:Seal Shield Ships New SILVER SEAL(TM) Washable, Antimicrobial Keyboard 2Health News:Healthcentral's Healthcare08 Site, an Interactive Health Care Issues Tool, Featured on washingtonpost.com 2Health News:An Event Added to Celebrate and Empower North Carolina Women 2Health News:ScienceBased Health Appoints Anne L. Coleman, MD, PhD to Scientific Advisory Board 2Health News:Transitions Optical Promotes Healthy Sight Through a Nationwide Integrated Advertising Campaign and the Launch of an Enhanced Consumer Web Site 2Health News:Transitions Optical Promotes Healthy Sight Through a Nationwide Integrated Advertising Campaign and the Launch of an Enhanced Consumer Web Site 3
(Date:12/15/2014)... , December 15, 2014 BerGenBio ... for aggressive drug resistant cancers, today announces that it ... private placing from new and existing investors. ... support the development of its pipeline of innovative cancer ... its lead drug candidate, BGB324, a first-in-class selective Axl ...
(Date:12/15/2014)... Pa. , Dec. 15, 2014  Inovio ... today it has been added to the NASDAQ ... Biotechnology Index will become effective upon market open ... Biotechnology Index is designed to track the performance ... classified as either biotechnology or pharmaceutical according to ...
(Date:12/15/2014)... -- Colorado and Washington State are not ... Oregon , Alaska , ... the November 2014 elections. Photo - ... The benefits of legalizing cannabis are manifold. There ... increased tax revenue for state and local governments, in addition ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... Chimerix, Inc., a pharmaceutical company developing ... clinical trial results for CMX157 demonstrating a favorable ... results from a series of preclinical studies showed ... activity against human immunodeficiency virus (HIV), including ...
... ANTONIO, and SAN FRANCISCO, Dec. 12, 2010 ... announced positive results from a Phase 2 clinical ... breast cancer during the 33rd Annual CTRC-AACR San ... investigational topoisomerase I inhibitor-polymer conjugate, is Nektar,s lead ...
Cached Medicine Technology:Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability 2Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability 3Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability 4Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability 5NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients 2NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients 3NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients 4NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients 5NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients 6NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients 7NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients 8NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients 9
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Icefire has ice crystals on the top of a cool blue iris....
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medicine Products: